rs12610022 — INSR

INSR rs12610022 — An Intronic Variant in the Insulin Receptor Gene

The insulin receptor (INSR) is the entry point for insulin signaling in every cell of the body. When insulin binds, it activates a receptor tyrosine kinase¹¹ A kinase is an enzyme that adds phosphate groups to target proteins, triggering a cascade of intracellular signals cascade that routes glucose into cells, stimulates glycogen synthesis, and suppresses glucose production by the liver. Disruption of INSR function — whether from rare mutations or common regulatory variants — is a central mechanism in insulin resistance and type 2 diabetes.

rs12610022 is an intronic variant located in intron 13 of INSR on chromosome 19p13.2. It is not a coding change and does not directly alter the insulin receptor protein sequence. Instead, as an intronic variant near a region known to harbor splicing regulatory elements, it may influence how the INSR gene is transcribed or spliced.

The Mechanism

The INSR gene produces two main protein isoforms, INSR-A and INSR-B, through alternative splicing²² Alternative splicing is a process where different exons of a gene are included or excluded from the final mRNA, producing distinct protein variants from a single gene of exon 11. INSR-B (with exon 11) is the dominant form in metabolic tissues — liver, muscle, and adipose — and mediates the classical glucose-lowering actions of insulin. INSR-A (without exon 11) has higher affinity for IGF-II and drives mitogenic rather than metabolic signaling. In type 2 diabetes, the INSR-A/INSR-B ratio is shifted toward the mitogenic isoform, reducing metabolic signal output per unit of insulin.

Intronic sequences flanking exon 11 contain splicing enhancers and silencers that control isoform balance. A variant in intron 13 — which lies downstream of the exon 11 splicing cassette — could plausibly influence secondary splicing events or INSR transcript stability, though the specific molecular effect of rs12610022 has not been experimentally confirmed. Its position in LD with functional exonic variants in the same gene (including rs2229431 in exon 13) means it may also act as a tag SNP for those nearby functional changes.

The Evidence

A sequencing study by Melkersson 2018³³ Melkersson 2018
Melkersson K. Sequencing of the insulin receptor (INSR) gene reveals association between gene variants in exon and intron 13 and schizoaffective disorder. Neuro Endocrinol Lett, 2018 conducted whole-gene INSR sequencing in 105 patients with schizophrenia or schizoaffective disorder and 60 healthy controls. The study identified rs12610022 (intron 13) as showing tendencies toward significant differences in allele and genotype distribution specifically in schizoaffective disorder patients versus controls — a finding consistent with the emerging hypothesis that impaired insulin receptor signaling in the brain contributes to psychotic illness. The study is small (165 total participants) and rs12610022 did not reach conventional GWAS thresholds independently; replication in larger cohorts is needed.

Separately, Kaminska et al. 2014⁴⁴ Kaminska et al. 2014
Kaminska D et al. Adipose tissue INSR splicing in humans associates with fasting insulin level and is regulated by weight loss. Diabetologia, 2014 demonstrated that adipose tissue expression of INSR-B correlates negatively with fasting insulin levels (p = 3×10⁻²²) across three independent cohorts, and weight loss — via bariatric surgery or caloric restriction — restores INSR-B expression. This establishes the biological plausibility that intronic regulatory variants influencing INSR isoform balance would have measurable metabolic consequences.

The G allele of rs12610022 is rare in Europeans (~6%) but substantially more common in East Asian populations (~58%), which may explain why metabolic associations have been difficult to detect in predominantly European study cohorts.

Practical Implications

For carriers of one or two G alleles, the evidence is too early for specific clinical guidance. The most actionable insight from INSR biology is that receptor sensitivity is modifiable: adipose INSR-B expression responds robustly to weight loss, meaning that reducing adipose mass directly upregulates the metabolically favorable isoform regardless of underlying genotype. Monitoring fasting insulin (rather than glucose alone) provides an earlier window into insulin signaling competence.

Interactions

rs12610022 lies in the same gene as several better-studied INSR variants. The rs2229431 exon 13 variant was the primary finding in the same Melkersson 2018 study, suggesting the intron 13 and exon 13 variants may tag a common haplotype. The widely studied rs1799817 (His1085His, exon 17) and rs2059807 have established associations with PCOS and insulin resistance in multiple ethnic populations. If you carry risk alleles at multiple INSR positions, the combined effect on receptor function warrants closer metabolic monitoring.